[
U.S. Food and Drug Administration Updates CAMZYOS ® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
[og_img]
https://www.investing.com/news/press-releases/us-food-and-drug-administration-updates-camzyos–mavacamten-label-to-reduce-echocardiography-monitoring-requirements-and-contraindications-93CH-3992116
Investing.com
U.S. Food and Drug Administration Updates CAMZYOS ® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Related articles
